Infections, Human Immunodeficiency Virus and Herpesviridae
5
0
0
5
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Treatment Research
11 treatments under study, led by Gsk1349572
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 5 trials
100.0%
+13.4% vs benchmark
0%
0 trials in Phase 3/4
0%
0 of 5 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 5 completed trials
Clinical Trials (5)
GSK1349572 Drug Interaction Study With Efavirenz
A Study to Assess the Relative Bioavailability of Tablet Formulations of GSK2248761 in Healthy Adult Subjects. SGN114435
GSK1349572 Drug Interaction Study With Fosamprenavir/Ritonavir
A Single Dose Escalation Study to Investigate the Safety, Tolerability and Pharmacokinetics of Intramuscular and Subcutaneous Long Acting GSK1265744 in Healthy Subjects
Relative Bioavailability Study of a Pediatric Granule Formulation of Dolutegravir
Research Network
Common Treatments
- Gsk13495722
- Ritonavir1
- Gsk2248761 Wbm Tablet Formulation 21
- Gsk2248761 Wbm Capsule1
- Gsk2248761 Wbm Tablet Formulation 11
Active Sponsors
- ViiV Healthcare5
- GSK5
- Shionogi2
Related Conditions
- Infection Human Immunodeficiency Virus1